A Phase 1/2a Study of Subretinal Administration of OpCT-001 Photoreceptor Precursor Cells Derived from IPSCs in Patients with Primary Photoreceptor Disease
Latest Information Update: 21 Mar 2025
At a glance
- Drugs OpCT 001 (Primary)
- Indications Retinal disorders
- Focus Adverse reactions; First in man
- Acronyms CLARICOR
- Sponsors BlueRock Therapeutics
- 18 Mar 2025 Planned End Date changed from 1 Aug 2030 to 1 Oct 2030.
- 18 Mar 2025 Planned primary completion date changed from 1 Aug 2029 to 1 Oct 2029.
- 18 Mar 2025 Status changed from not yet recruiting to recruiting.